Pemphigus and COVID-19 : Critical overview of management with a focus on treatment choice
© 2020 Wiley Periodicals LLC..
COVID-19 is a serious multisystem disease caused by severe acute respiratory syndrome coronavirus 2. Due to the COVID-19 crisis, that still keeps its impacts worldwide, numerous scheduled medical activities have been postponed and this interruption has a potential to modify the management of many cutaneous conditions including pemphigus. This narrative review aims to discuss the management of pemphigus in the era of COVID-19, considering the necessity to balance suitable pemphigus treatment with minimal risk of COVID-19-related mortality and morbidity. The data on the effect of treatments used for pemphigus on COVID-19 are limited. However, the evidence to manage patients properly is evolving and our knowledge is updated. Current expert recommendations include that patients with pemphigus should be informed clearly to avoid mismanagement and they should be monitored regularly for symptoms of COVID-19. Patients with mild disease can be managed with topical or intralesional corticosteroids, dapsone, or doxycycline. Systemic corticosteroids should be tapered to the lowest effective dose during the pandemic. Prednis(ol)one ≤10 mg/d can be continued in patients with COVID-19 while prednis(ol)one >10 mg/d may be reduced considering the activity of the disease. Conventional immunosuppressive therapies should only be discontinued in confirmed cases of COVID-19. Postponing rituximab treatment should be considered on a case by case basis. Intravenous immunoglobulin is not likely to increase the risk of infection and may be considered a safe option in patients with COVID-19. Given the psychological burden brought by COVID 19, online or face-to-face psychological support programs should be considered.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Dermatologic therapy - 33(2020), 6 vom: 03. Nov., Seite e14265 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Elmas, Ömer Faruk [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 12.01.2021 Date Revised 12.01.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dth.14265 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314549463 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314549463 | ||
003 | DE-627 | ||
005 | 20231225152952.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dth.14265 |2 doi | |
028 | 5 | 2 | |a pubmed24n1048.xml |
035 | |a (DE-627)NLM314549463 | ||
035 | |a (NLM)32882079 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Elmas, Ömer Faruk |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pemphigus and COVID-19 |b Critical overview of management with a focus on treatment choice |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.01.2021 | ||
500 | |a Date Revised 12.01.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a COVID-19 is a serious multisystem disease caused by severe acute respiratory syndrome coronavirus 2. Due to the COVID-19 crisis, that still keeps its impacts worldwide, numerous scheduled medical activities have been postponed and this interruption has a potential to modify the management of many cutaneous conditions including pemphigus. This narrative review aims to discuss the management of pemphigus in the era of COVID-19, considering the necessity to balance suitable pemphigus treatment with minimal risk of COVID-19-related mortality and morbidity. The data on the effect of treatments used for pemphigus on COVID-19 are limited. However, the evidence to manage patients properly is evolving and our knowledge is updated. Current expert recommendations include that patients with pemphigus should be informed clearly to avoid mismanagement and they should be monitored regularly for symptoms of COVID-19. Patients with mild disease can be managed with topical or intralesional corticosteroids, dapsone, or doxycycline. Systemic corticosteroids should be tapered to the lowest effective dose during the pandemic. Prednis(ol)one ≤10 mg/d can be continued in patients with COVID-19 while prednis(ol)one >10 mg/d may be reduced considering the activity of the disease. Conventional immunosuppressive therapies should only be discontinued in confirmed cases of COVID-19. Postponing rituximab treatment should be considered on a case by case basis. Intravenous immunoglobulin is not likely to increase the risk of infection and may be considered a safe option in patients with COVID-19. Given the psychological burden brought by COVID 19, online or face-to-face psychological support programs should be considered | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a IVIg | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a pandemic | |
650 | 4 | |a pemphigus | |
650 | 4 | |a rituximab | |
650 | 7 | |a Dermatologic Agents |2 NLM | |
650 | 7 | |a Glucocorticoids |2 NLM | |
650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Dapsone |2 NLM | |
650 | 7 | |a 8W5C518302 |2 NLM | |
650 | 7 | |a Doxycycline |2 NLM | |
650 | 7 | |a N12000U13O |2 NLM | |
700 | 1 | |a Demirbaş, Abdullah |e verfasserin |4 aut | |
700 | 1 | |a Türsen, Ümit |e verfasserin |4 aut | |
700 | 1 | |a Atasoy, Mustafa |e verfasserin |4 aut | |
700 | 1 | |a Lotti, Torello |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 6 vom: 03. Nov., Seite e14265 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2020 |g number:6 |g day:03 |g month:11 |g pages:e14265 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.14265 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2020 |e 6 |b 03 |c 11 |h e14265 |